Status:
WITHDRAWN
(-)-Epicatechin and Pulmonary Arterial Hypertension
Lead Sponsor:
University of California, San Francisco
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Pulmonary arterial hypertension (PAH) is a progressive disease that results in severe activity limitation and death. There are few treatments for PAH and the available medications are expensive, diffi...
Eligibility Criteria
Inclusion
- Male or female age 18 or older
- NYHA Class II-!V
- 6 minute walk distance \< 450 meters
- Outpatients with suspected WHO group I PAH or and established diagnosis of WHO group I PAH undergoing clinically indicated right heart catheterization
- Written informed consent obtained from subject and ability for subject to comply with the requirements of study
Exclusion
- Pregnancy
- Breast feeding
- Systolic blood pressure \<100 or \>160
- History of migraine headaches
- Allergy or intolerance to chocolate, tea or wine
- Subject is considered unsuitable for the study in the opinion of the investigator, nurse practitioner, or study physician for any other reason
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01880866
Start Date
July 1 2013
End Date
January 1 2014
Last Update
September 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF
San Francisco, California, United States, 94110